GPT and hepatobiliary disorder: Similarly, the most common TEAEs leading to discontinuation of tislelizumab were also in the “hepatobiliary disorders” and “investigations” system organ classes (6.7% and 3.9% of patients, respectively), and included immune-mediated hepatitis and ALT increased (each 3.3%).